Steroid hormone receptors are generally intracellular receptors, which initiate signal transduction for steroid hormones such as glucocorticoid and mineralocorticoid, which lead to changes in gene expression. Steroid receptor agonists show their effects by decreasing vasodilation and permeability of capillaries, as well as decreasing leukocyte migration sites of inflammation. They also inhibit neutrophil apoptosis and demargination, the inhibition of phospholipase A2, decreases the formation of arachidonic acid derivatives. Additionally, they inhibit NF-Kappa B and other inflammatory transcription factors, they also promote anti-inflammatory genes like interleukin-10. Steroid receptor agonists are indicated as an anti-inflammatory or immunosuppressive drug for allergic, dermatologic, gastrointestinal, hematologic, ophthalmologic, nervous system, renal, respiratory, rheumatologic, infectious, endocrine, or neoplastic conditions as well as in organ transplant. AbbVie, Pfizer, Ocular Therapeutix, Novartis, Bayer, and EyePoint Pharma are some of the major players in the steroid receptor agonists market.
Key Market Developments:
- In Apr 2023, the NMPA (China) approved has approved the clinical trial application (CTA) of Ocular Therapeutics to initiate a Phase III registrational study in the country to evaluate DEXTENZA in subjects following ophthalmic surgery.
- In May 2023, Formosa Pharmaceuticals preregistered Clobestol propionate nanoparticles for ocular inflammation and ocular pain in the USA.
Approved Drug Molecules and Brand Names for Steroid Receptor Agonists:
- Prednisone
- Dexamethasone injection
- Ozurdex (Dexamethasone intravitreal implant)
- Prednisone delayed-release tablet
- Calcipotriol/betamethasone dipropionate
- Solu-Cortef (Hydrocortisone sodium succinate injection)
- Clobetasol propionate topical
- Dextenza (Dexamethasone punctal plug)
- Beclometasone/formoterol
- Prednisolone acetate ophthalmic suspension
- Maxidex (Dexamethasone eye drops, suspension)
- Enstilar (Calcipotriene/betamethasone dipropionate)
- Loteprednol etabonate
- Synacthen Depot (Cosyntropin)
- Triesence (Triamcinolone acetonide injectable suspension)
- Betamethasone dipropionate
- Durezol (Difluprednate ophthalmic emulsion)
- Duobrii (Halobetasol/tazarotene)
- Advantan (Methylprednisolone aceponate)
- Dexycu (Dexamethasone intraocular injection)
- Retisert (Fluocinolone acetonide intravitreal implant)
- Kenalog-40 (Triamcinolone acetonide injection suspension)
- Desonate (Desonide gel)
- Eysuvis (Loteprednol etabonate nano-suspension 0.25%)
- FML, FML Forte (Fluorometholone ophthalmic suspension)
- Wynzora (Calcipotriene/betamethasone dipropionate)
- Desonide cream/ointment/lotion
- Clipper (Beclometasone)
- Jemdel (Halobetasol propionate topical)
- Tarpeyo (Budesonide)
- Betamethasone sodium phosphate/betamethasone acetate injection
- Impoyz (Clobetasol)
- Inveltys (Loteprednol etabonate nano-suspension 1%)
- Betnovate (Betamethasone valerate)
- Betamethasone valerate foam
- Clenil Modulite (Beclometasone pressurised metered-dose inhaler)
- Flarex (Fluorometholone acetate ophthalmic suspension)
- Vexol (Rimexolone ophthalmic)
- Dexamethasone intracanalicular insert (OTX-DED)
- Budesonide Clickhaler (Budesonide dry-powder inhaler)
- Calcort (Deflazacort)
- Eumovate (Clobetasone butyrate)
- Beclomethasone dipropionate
Drugs under the Pipeline for Steroid Receptor Agonists:
- Airsupra (Budesonide/Salbutamol)
- Dexamethasone ophthalmic (EGP-437)
- Bexarotene/Betamethasone dipropionate (LAS 41004)
- Captisol-enabled Budesonide
- DexaSite (Dexamethasone 0.1% in DuraSite)
- Synbitide HFA MDI (Budesonide/Procaterol)
- Clobetasol nanosuspension (APP13007)
- Clobetasol propionate ophthalmic nanoemulsion 0.05% (SVT-15473)
- orBec (Beclomethasone dipropionate oral)
- Betamethasone/Calcipotriol (BFH 772)
- Cortiject (Dexamethasone palmitate)
- DSP-Visulex (Dexamethasone sodium phosphate ophthalmic)
- Rivelin Clobetasol patch (Clobetasol propionate oral)
- TBS-5
- Dexamethasone (IBE-814)
Clinical Activity and Developments of Steroid Receptor Agonists:
Currently, there are about 59 drug products in steroid receptor agonists, including more than 30 approved ones, and other drug molecules are in clinical trial phases.
- In Feb 2023, Interface Biologics conducted preclinical trials in retinitis pigmentosa in Canada for Dexamethasone intravitreal implant.
- In May 2023, AFYX Therapeutics conducted preclinical trials in aphthous stomatitis in Denmark for Clobetasol propionate oral.
|
Molecule Name |
Number of Studies |
|
Airsupra (Budesonide/Salbutamol) |
8 |
|
Dexamethasone ophthalmic (EGP-437) |
7 |
|
Bexarotene/Betamethasone dipropionate (LAS 41004) |
6 |
|
Captisol-enabled Budesonide |
5 |
|
DexaSite (Dexamethasone 0.1% in DuraSite) |
3 |
|
Synbitide HFA MDI (Budesonide/Procaterol) |
3 |
|
Clobetasol nanosuspension (APP13007) |
3 |
|
Clobetasol propionate ophthalmic nanoemulsion 0.05% (SVT-15473) |
3 |
|
orBec (Beclomethasone dipropionate oral) |
3 |
|
Betamethasone/Calcipotriol (BFH 772) |
2 |
|
Cortiject (Dexamethasone palmitate) |
1 |
|
DSP-Visulex (Dexamethasone sodium phosphate ophthalmic) |
1 |
|
Rivelin Clobetasol patch (Clobetasol propionate oral) |
1 |
|
TBS-5 |
1 |
|
Dexamethasone (IBE-814) |
1 |
Target Indication Analysis of Steroid Receptor Agonists
Steroid receptor agonists are marketed for the treatment of ankylosing spondylitis, asthma, chronic obstructive pulmonary disease, polymyalgia rheumatica, psoriatic arthritis, rheumatoid arthritis, uveitis, atopic dermatitis, ulcerative colitis, plaque psoriasis, IgA nephropathy, dry eyes, ocular inflammation, ocular pain, allergic conjunctivitis, duchenne muscular dystrophy, and others. Moreover, some of the Steroid receptor agonists are in clinical trial phases for conditions such as diabetic macular edema, meibomianitis, retinal vein occlusion, post-operative inflammation, and pain, Crohn’s disease, radiation injuries, lichen planus, aphthous stomatitis, and others.
Regional Analysis of Steroid Receptor Agonists
Steroid Receptor Agonists Market
Globally, at least 2.2 billion people have vision impairment, according to the World Health Organization. Approximately 1.71 billion people have musculoskeletal conditions worldwide, with 441 million people in high-income countries, followed by the Western Pacific region (427 million) and the South East Asia region (369 million). According to a research report, there were approximately 40 million deaths in 2019 resulting from skin diseases, where the highest number of new cases and deaths in South Asia. GSK’s products include Dermovate, Betrnovate, Cutivate, and Eumovate for inflammatory skin conditions had a total revenue of US$ 252 million in the year 2022. Ocular Therapeutix’s Dextenza’s patents for the USA are expected to expire by 2030.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Frequently Asked Questions
Prednisone, Dexamethasone injection, Ozurdex (Dexamethasone intravitreal implant), Prednisone delayed-release tablet, Calcipotriol/betamethasone dipropionate, Solu-Cortef (Hydrocortisone sodium succinate injection), Clobetasol propionate topical are the few approved steroid receptor agonists.
AbbVie, Pfizer, Ocular Therapeutix, Novartis, Bayer, and EyePoint Pharma are some of the major players in the steroid receptor agonists market.
Major indications for steroid receptor agonists are ankylosing spondylitis, asthma, chronic obstructive pulmonary disease, polymyalgia rheumatica, psoriatic arthritis, rheumatoid arthritis, uveitis, atopic dermatitis, ulcerative colitis, plaque psoriasis, and others.
There are a total of 15 molecules in the phase-I/II clinical development for steroid receptor agonists.
- AbbVie
- Pfizer
- Edgemont Pharmaceuticals
- Eli Lilly & Company
- Bausch Health Companies
- Novo Nordisk
- CSPC Pharma
- HEC Pharm
- Otsuka Pharmaceutical
- Zhejiang Huahai Pharma